中国医学前沿杂志（电子版）2025，Vol.17Issue(4)：19-23,5.DOI:10.12037/YXQY.2025.04-04
西藏地区非转移性乳腺癌患者常用化疗方案及剂量强度分析的真实世界研究
A real-world study of commonly used chemotherapy regimens and dose-intensity analysis in patients with non-metastatic breast cancer in Tibet
摘要
Abstract
Objective To understand the clinicopathological characteristics and current status of diagnosis and treatment of stage Ⅰ-Ⅲ breast cancer in Tibet,and to provide reference for standardized diagnosis and treatment of breast cancer in Tibet.Methods A total of 233 cases of Tibetan breast cancer patients were retrospectively collected from July 2016 to September 2023 in the People's Hospital of Tibet Autonomous Region,and a total of 71 cases of stage Ⅰ-Ⅲ breast cancer patients were selected and analyzed for molecular typing,treatment regimen,chemotherapeutic drug dosage intensity,and the incidence of adverse reactions.Results The mean age of the patients was 51 years old,and 1.41%,47.89%and 50.70%of them had stage Ⅰ,Ⅱ and Ⅲ tumors,respectively.HR+HER2-,HER2+and TNBC accounted for 46.48%(33 cases),26.76%(19 cases)and 26.76%(19 cases),respectively.The dose intensity of commonly used chemotherapeutic agents cyclophosphamide,docetaxel,paclitaxel and platinum could reach the dose recommended by each guideline,with epirubicin being lower than the recommended dose.The most common adverse events include leukopenia(63.39%),hepatic injury(43.66%),thrombocytopenia(30.99%),and erythrocytopenia(23.94%).Conclusions The proportion of stageⅠ-Ⅲ breast cancer in Tibet is relatively high,and it is necessary to strengthen the popularization of science and early cancer screening in the region.The overall treatment plan is basically in line with the guideline,in which the proportion of anti-HER-2 treatment needs to be further improved,and the application of the plan can be more refined in the future.关键词
藏族/乳腺癌/辅助化疗/剂量强度/不良反应Key words
Tibetan/Breast cancer/Adjuvant chemotherapy/Dose intensity/Adverse effects引用本文复制引用
色珍,次仁曲珍,张梦婷,桑旦旺姆,索朗普赤,赵玉兰,马玉超,李逸群..西藏地区非转移性乳腺癌患者常用化疗方案及剂量强度分析的真实世界研究[J].中国医学前沿杂志（电子版）,2025,17(4):19-23,5.基金项目
Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(2023-RW320-10) 中国医学科学院中央性公益性科研院所基本科研业务费-重大任务及行业支撑(2023-RW320-10) （2023-RW320-10）
